“Selective JAK1 Inhibition Using Upadacitinib for the Management of Inflammatory Bowel Diseases: The Powerful Pill”, Can IBD Today, vol. 1, no. S11, pp. 2–11, Nov. 2023, doi: 10.58931/cibdt.2023.1S1121.